InvestorsHub Logo
Post# of 252588
Next 10
Followers 831
Posts 120032
Boards Moderated 17
Alias Born 09/05/2002

Re: DewDiligence post# 66199

Wednesday, 09/24/2008 5:48:51 AM

Wednesday, September 24, 2008 5:48:51 AM

Post# of 252588
ANTICOAGULANT INDEX

[Added entry for NICE approval of Pradaxa. Please
see MNTA ‘ReadMeFirst’ for info on M118.
]



General
#msg-25160571 Anticoagulant market has large potential (WSJ)
#msg-26899903 Anticoagulant market has large potential (graphic)
#msg-26451612 Venous thromboembolism is a big, big problem
#msg-18759853 Overview of the new oral anticoagulants
#msg-26701803 Technical overview of traditional anticoagulants


Xarelto (rivaroxaban)
#msg-30972846 EMEA approves Xarelto for VTE prevention
#msg-31857009 Bayer accelerates Xarelto development
#msg-31073048 JNJ submits NDA for VTE prevention
#msg-29662519 Rivaroxaban rationale
#msg-24337258 Bayer plans 50,000(!)-patient study


Apixaban
#msg-31742223 Apixaban fails vs Lovenox in phase-3
#msg-32024540 Tepid phase-2 results in ACS
#msg-19134406 PFE, BMY ink $1B collaboration
#msg-29928836 Seventh and eighth phase-3 trials begin
#msg-21044973 Apixaban non-inferior to Warfarin in phase-2


Pradaxa (dabigatran)
#msg-32382343 NICE approves Pradaxa in only six months
#msg-27956748 EU approves Pradaxa for VTE prevention
#msg-26086079 BI completes enrollment of huge AF trial
#msg-25152872 BI starts phase-2 in ACS
#msg-21155926 Dabigatran non-inferior to Lovenox in VTE prevention


Lovenox
#msg-11669012 Lovenox more cost-effective than heparin?
#msg-10569101 Arixtra bests Lovenox in ACS


Miscellaneous
#msg-31161411 AZD0837 comes out of the closet
#msg-30170392 ARYX ATI-5923: A safer warfarin?
#msg-29601951 Ablynx ALX-0081 begins phase-1b in PCI
#msg-27043616 ART-123 from Artisan Pharma
#msg-22938795 AVE5026 and otamixaban (SR123781 dropped Feb08)
#msg-26298260 Biotinylated idraparinux causes excess bleeding
#msg-31950663 Daiichi Sankyo phase-2 data for DU-176b
#msg-30353872 MYGN MPC-0920 begins phase-1
#msg-31461171 NUVO reports phase-1b data for NU172
#msg-27187973 Paion’s Solulin completes phase-1
#msg-28742653 Paion acquires flovagatran rights
#msg-32171800 Regado reports phase-1 data for aptamer
#msg-30965016 LLY terminates FXa program

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.